文献速递类风湿关节炎其他结缔组织病

系统性自身免疫病中利妥昔单抗免疫原性高于类风湿关节炎:奥法妥木单抗可作为替代治疗

Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该回顾性研究纳入2012—2017年接受利妥昔单抗(RTX)治疗的199例患者(类风湿关节炎124例、其他系统性自身免疫病75例),其中62例检测了抗药抗体。其他系统性自身免疫病的RTX抗药抗体阳性率显著高于类风湿关节炎,且多数免疫化患者出现输注反应或疗效丧失;奥法妥木单抗在3例免疫化的原发性干燥综合征患者中实现完全缓解。

要点

  • 其他系统性自身免疫病的RTX抗药抗体频率显著高于类风湿关节炎。
  • 出现输注反应或疗效丧失时应检测RTX抗药抗体,尤其非洲裔患者。
  • 免疫化患者或可安全有效地换用奥法妥木单抗,但需进一步评估。

核心结论

  • 利妥昔单抗免疫化在其他系统性自身免疫病中比类风湿关节炎更常见,奥法妥木单抗可能是免疫化患者的替代治疗。

研究设计与样本

  • 单中心回顾性研究,纳入2012—2017年接受利妥昔单抗治疗的类风湿关节炎或其他系统性自身免疫病患者199例(类风湿关节炎124例、其他系统性自身免疫病75例),其中62例检测了抗药抗体。

主要发现

  • 62例检测者中14例抗药抗体阳性,类风湿关节炎3/35(8.6%)、其他系统性自身免疫病11/27(40.7%),P=0.0047。
  • 全部治疗人群中抗药抗体频率类风湿关节炎2.4%、其他系统性自身免疫病14.7%,P=0.0026。
  • 多数免疫化患者(11/14)在第二或后续RTX周期出现输注反应,2/14出现疗效丧失。
  • 免疫化预测因素为其他系统性自身免疫病较类风湿关节炎(78.6% vs 21.4%,P=0.026,校正OR=5.35[1.43-54.75])及非洲裔(57.1% vs 4.2%,P<0.001,校正OR=9.25[5.08-302.12])。
  • 联合免疫抑制治疗未提供抗免疫化保护;3例免疫化的原发性干燥综合征患者经奥法妥木单抗治疗后疾病完全缓解。

关键数值与推荐

  • 抗药抗体检测阳性率:类风湿关节炎8.6%(3/35)vs 其他系统性自身免疫病40.7%(11/27),P=0.0047。
  • 全部治疗人群抗药抗体频率:类风湿关节炎2.4% vs 其他系统性自身免疫病14.7%,P=0.0026。
  • 免疫化预测因素:其他系统性自身免疫病较类风湿关节炎校正OR=5.35[1.43-54.75],非洲裔校正OR=9.25[5.08-302.12]。

临床怎么用

  • 对出现输注反应或疗效丧失的RTX治疗患者应检测抗药抗体,非洲裔及其他系统性自身免疫病患者尤需警惕。
  • 免疫化患者可考虑换用奥法妥木单抗,但该替代方案在其他系统性自身免疫病中尚需进一步评估。

局限性

  • 单中心回顾性设计,仅62/199例检测了抗药抗体,可能存在选择偏倚。
  • 奥法妥木单抗替代治疗仅基于3例原发性干燥综合征患者的观察,证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The frequency and consequences of anti-drug antibodies to rituximab (RTX-ADA) are not well known in RA and even less in other systemic auto-immune diseases (sAID). We aimed to evaluate the frequency, consequences and predictive factors of RTX-ADA in RA and sAID. METHODS: All patients presenting with RA or other sAID treated with RTX from 2012 to 2017 in our tertiary reference centre for sAID were retrospectively studied. Patients who were tested for RTX-ADA were identified. RESULTS: One hundred and ninety-nine patients were treated with RTX (RA: 124, other sAID: 75). Among 62/199 (31.1%) tested for RTX-ADA, 14 were positive: 3/35 RA (8.6%) and 11/27 (40.7%) other sAID, (P = 0.0047). Among the whole RTX-treated populations, the frequency of RTX-ADA was 2.4% and 14.7% (P = 0.0026) in RA and sAID, respectively. Most of the immunized patients had infusion reactions to second or subsequent RTX cycles (11/14) and loss of efficacy (2/14). Predictive factors of immunization were sAID vs RA (78.6% vs 21.4%, P = 0.026, adjusted odds ratio (OR) = 5.35[1.43-54.75]) and African ethnicity (57.1% vs 4.2%, P < 0.001, adjusted OR = 9.25 [5.08-302.12]). Associated immunosuppressive therapy did not protect against immunization. Three patients with pSS immunized against RTX were treated with ofatumumab with complete remission of their disease. CONCLUSION: Immunization against RTX is more frequent in other sAID than in RA. Testing for RTX-ADA must be performed in patients with infusion reactions or loss of efficacy especially if they are of African origin. Immunized patients might be treated efficiently and safely with ofatumumab. This alternative should be further evaluated for sAID.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Combier A, Nocturne G, Henry J, et al. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy. Rheumatology (Oxford). 2020. PMID: 31613955. doi:10.1093/rheumatology/kez430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。